We believe this site might serve you best:

United States

English Continue

This country code will remain if no action is taken to change it.

Don't see your country?
Promega Corporation

RNasin® Ribonuclease Inhibitor Protocol

Literature # 9PIN211

RNasin® Ribonuclease Inhibitor has broad-spectrum RNase inhibitory properties. The 50kDa protein exerts its inhibitory effect by noncovalently binding to RNases at a 1:1 ratio. The Ki value for the binding of RNasin® Ribonuclease Inhibitor to RNase (e.g., RNase A) is approximately 10–14M. Promega offers two different preparations: Natural RNasin® Ribonuclease Inhibitor (Cat.# N2111, N2115) and Recombinant RNasin® Ribonuclease Inhibitor (Cat.# N2511, N2515). These products are purified using a combination of ion exchange and affinity chromatography, and Natural and Recombinant RNasin® Ribonuclease Inhibitors are devoid of DNA exonuclease and endonuclease activity and RNase activity. In addition to its ability to inhibit RNase activity, RNasin® Ribonuclease Inhibitor has been shown to inhibit angiogenesis induced by angiogenin, basic fibroblast growth factor (bFGF) and sodium orthovanadate. Moreover, RNasin® Ribonuclease Inhibitor reduced neovascularization evoked by implanted tumor cells and significantly inhibited tumor growth in a murine model.

Printed in USA. Revised 8/13.

 

PDF Icon Complete Protocol PDF (150kb)

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.

Scientists at Your Service

Scientists at Your Service

We offer a range of services to help you succeed using Promega technologies. From product training to set up of automated systems and development of custom applications—our scientific support goes beyond the basics.

Ask us! We are here to help you.